Cases & Deals

  • Home
  • Practices
  • sanofi-aventis enters into $900 million R&D/equity

Share

sanofi-aventis enters into $900 million R&D/equity

December 2007

Client(s) sanofi-aventis S.A.

Jones Day advised sanofi-aventis in its $400 million global biotech collaboration arrangement with and equity investment in Regeneron, with up to $475 million of additional research funding.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.